Announcing Our Newest Sponsor: Actelion

October 07,2013

Actelion_K_RGB199Team PHenomenal Hope is pleased to welcome Actelion as a company sponsor of our team. Actelion Pharmaceuticals is a biopharmaceutical company headquartered in Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

“Actelion has a long history of generous philanthropic support in the pulmonary hypertension community,” said Dr. Patricia George, manager of Team PHenomenal Hope, “and so we are truly excited to have them join us on this adventure.” Actelion is providing support, not only to get the team to the starting line, but also in helping us all get to the finish line in our race towards a cure for pulmonary hypertension. “We are excited to join Team PHenomenal Hope in their Race Across America, and look forward to being there at the starting line in California and joining them at finish line in Annapolis,” announced Kelly Lewis, Senior Director, Medical Strategy and Planning at Actelion.

Actelion developed Tracleer (bosentan) the first oral medication to specifically treat pulmonary hypertension, which came on the market in 2001.  Subsequently, the company contributed Ventavis (inhaled iloprost) and Veletri (IV epoprostenol) to the market, further enhancing our armamentarium against PAH.

Continuing to pursue the forefront in developing PAH-specific therapies, this year Actelion is bringing to market a new medication, Opsumit (macitentan), a drug developed from a tailored drug development process, shown in the event-driven SERAPHIN study to significantly reduce morbidity and mortality (Pulido et al, NEJM 2013; 369).

This upcoming year will certainly be an exciting year for Team PHenomenal Hope and its newest sponsor, Actelion Pharmaceuticals.

 

Leave a Reply